`
`EN THE Cl...AlMS:
`
`Claims ill-~17, 23~27, 295, 34a 3769, ill-43, and 50—57 were previnnsly cancelled. Claim
`
`5 is herein cancelled. Claims l—3, 7-l3, 18, ill, ’22, 283 30, 31, 33, 36, 40, and 49 have been
`
`amended herein“ New claims 58-77 are presented herein. All of the pending claims are
`
`presented below. This listing at claims will replace all prior versions and listings of claims in the
`
`application. Please enter these claims as amended.
`
`Marin " at" the Claims:
`
`
`
`
`1.
`
`(Currently amended) A hispeeific antibody eemprising a first antigen—binding site that
`
`binds delimit} l at“ ErbB-‘Z and a second antigen—binding site that binds,diligent}lint": Ei‘bB—Sg
`
`wherein the antibody eaneedeee its}
`
` \ a liganddndueed reeertter functien ntilirhlid on a
`
`ErbB—Z and ErbBé positive eell.
`
`2.
`
`(Currently amended) The bispeeifie antibody of claim l, wherein the antibody earl
`
`ledaeeiiilnixx ligandsindueed growth ef an lirbB—2 and liith~3 positive cell,
`
`3.
`
`(Currently amended) The bispeciiie antibody of claim 25 wherein the antibody ean
`
`redaee redraw ligandwindnced growth of an ErbB—Q and ErbBuB pesitive eells wherein said the
`
`cell has at least lOOflOO ErbB«2 eelhsnrt‘ace receptors per cell.
`
`4.
`
`
`(Currently amended) The bispecilie antibody of claim it wherein said the eell is an
`
`MCFJ cell, an SKBR—Ft cell, NCl—NS? cell , an 8x903 cell, an Ell—474 cell er a llM’l‘ l eell‘
`
`5.
`
`6.
`
`(Cancelled).
`
`{Previously presented) The hispeeilie antibody of claim l, wherein the second antigen—
`
`binding site interferes with binding of an Eth—3 ligand to ErbBG.
`
`